FDA approves Lutathera for pediatric GEP-NET patients 12 and older
The agency's approval extends use of lutetium Lu 177 dotatate to adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
The FDA approved lutetium Lu 177 dotatate, marketed as Lutathera by Advanced Accelerator Applications USA, Inc., a Novartis company, on April 23, 2024, for a new patient population. The approval covers pediatric patients 12 years and older with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NET).1
The FDA's notice does not specify dosing, trial data, or endpoints supporting this pediatric approval, nor does it provide prior regulatory history for the drug in other populations. No additional details on clinical trial results, administration schedule, or next steps were included in the source record.
Readers seeking further specifics on the approval, including underlying study data or labeling changes, should consult the full FDA prescribing information or related regulatory filings, as this notice does not contain that information.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.